Effect of olive and grape seed oil on lipid profile

Effects of olive and grape seed oil consumption on metabolic responses and lipid profiles in hyperlipidemic patients

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2014070218329N1

Enrollment

Registered

2015-02-13

Start date

2014-03-22

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hyperlipidemia. Hyperlipidaemia, unspecified

Interventions

Intervention 1: Intervention 1: 20 mL refined grape seed oil/day (XXX company, Italy) + Having Step I diet (for 6 weeks). Intervention 2: Intervention 2: 20 mL refined olive oil/day (Kokab Olive Oil C

Lifestyle

Intervention 1: 20 mL refined grape seed oil/day (XXX company, Italy) + Having Step I diet (for 6 weeks)

Intervention 2: 20 mL refined olive oil/day (Kokab Olive Oil Company, Qazvin, Iran) + Having Step I diet (for 6 weeks)

Intervention 3: control: Receiving no oil and consuming + Having step I diet (for 6 weeks)

Eligibility

Sex/Gender

All

Age

30 Years to 60 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: At least one of lipid profile indicators should be elevated (TC=200, HDL=40, LDL=130? TG=150), 30-60 years of age, lack of cardiac, renal or hepatic disease and not using antioxidant supplements, no pregnancy or lactation. Exclusion criteria: Change in physical activity, diet or medications; using less than 80% of the given oil.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Blood pressure. Timepoint: At the start of intervention and 6 weeks after intervention. Method of measurement: Mercurial column sphygmomanometer.;Total cholesterol. Timepoint: At the start of intervention and 6 weeks after intervention. Method of measurement: Enzymatic.;High density lipoprotein (HDL). Timepoint: At the start of intervention and 6 weeks after intervention. Method of measurement: Enzymatic.;Triglyceride. Timepoint: At the start of intervention and 6 weeks after intervention. Method of measurement: Enzymatic.;Low density lipoprotein (LDL). Timepoint: At the start of intervention and 6 weeks after intervention. Method of measurement: Friedewalds formula.;Very low density lipoprotein (VLDL). Timepoint: At the start of intervention and 6 weeks after intervention. Method of measurement: Enzymatic.;Weight. Timepoint: At the start of intervention and 6 weeks after intervention. Method of measurement: Seca scale.;Serum glucose. Timepoint: At the start of intervention and 6 weeks after intervention. Method of measurement: Enzymatic.;Height. Timepoint: At the start of intervention and 6 weeks after intervention. Method of measurement: Seca scale.	—

Measure

Time frame

Blood pressure. Timepoint: At the start of intervention and 6 weeks after intervention. Method of measurement: Mercurial column sphygmomanometer.;Total cholesterol. Timepoint: At the start of intervention and 6 weeks after intervention. Method of measurement: Enzymatic.;High density lipoprotein (HDL). Timepoint: At the start of intervention and 6 weeks after intervention. Method of measurement: Enzymatic.;Triglyceride. Timepoint: At the start of intervention and 6 weeks after intervention. Method of measurement: Enzymatic.;Low density lipoprotein (LDL). Timepoint: At the start of intervention and 6 weeks after intervention. Method of measurement: Friedewalds formula.;Very low density lipoprotein (VLDL). Timepoint: At the start of intervention and 6 weeks after intervention. Method of measurement: Enzymatic.;Weight. Timepoint: At the start of intervention and 6 weeks after intervention. Method of measurement: Seca scale.;Serum glucose. Timepoint: At the start of intervention and 6 weeks after intervention. Method of measurement: Enzymatic.;Height. Timepoint: At the start of intervention and 6 weeks after intervention. Method of measurement: Seca scale.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAkram Naghdipour Biregani

Shahid Sadoughi University of medical sciences, Yazd, Iran

naghdipour86@yahoo.com+31 52634919

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Mar 2, 2026